Training equips midwives in rural Sololá to identify cardiac warning signs in newborns and improve early referral for life-saving care. By equipping midwives with practical screening knowledge, we are strengthening frontline care and expanding access to early diagnosis and life-saving treatment.” — Christina Lindseth, International Director of Cardiac Care SOLOLA, GUATEMALA, December 23, 2025 / EINPresswire.com / -- Love Without Boundaries (LWB), an international charity serving children worldwi

A non-invasive, high-accuracy surveillance test for bladder cancer has the potential to improve patient experience, streamline workflows, and reduce overall cost of care” — Megann Vaughn Watters, Vice President of New Ventures for Labcorp BOSTON, MA, UNITED STATES, December 23, 2025 / EINPresswire.com / -- Cellens, Inc., a cancer diagnostics company pioneering a new mechanobiology and AI-driven platform, BioFeel™, for non-invasive cancer detection, has raised a $6.5M Series Seed round. The finan

Delivery Method: Via Email Product: Drugs Recipient: Pinnacle Professional Research dba Pinnacle Peptides 1001 N Elm Street, Suite 31 Greensboro , NC 27401 United States service@pinnaclepeptides.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER December 12, 2025 RE: 719337 Pinnacle Professional Research dba Pinnacle Peptides: This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address ht

Delivery Method: Via Electronic Mail - Delivery and Read Receipt Requested Product: Drugs Recipient: Recipient Name Aaron M. Schneider Recipient Title Chief Pharmacy Officer & Owner Revive Rx LLC dba Revive Rx Pharmacy 3831 Golf Drive, Suite A Houston , TX 77018-5218 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER WL # 709509 September 22, 2025 Dear Mr. Schneider: From January 27, 2025, to February 7, 2025, a U.S. Food and Drug Administra

Delivery Method: Via Email Reference #: 320-26-29 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Zhou Yigang Recipient Title Production Manager Guangdong Renhe Guozhuang Biotechnology Co., Ltd. No. 5, Tongfu Road, Xicheng Industrial Area Renhe Town Baiyun Qu Guangzhou Shi Guangdong Sheng , 510080 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-29 December 16, 2025 Your facility is registered with the United States Food

The FDA has become aware of a potentially high-risk device issue. The FDA will keep the public informed and update this web page as significant new information becomes available. Affected Product The FDA is aware that Integra LifeSciences has issued a letter to affected customers recommending certain Codman Microsensor Basic Kits and Cerelink ICP Sensor Basic Kits be removed from where they are used or sold. Affected devices: Full list of affected lots What to Do Identify affected lots and remov

CAMBRIDGE, Mass., Dec. 23, 2025 /PRNewswire/ -- Next Gen Diagnostics (NGD) today announced that January 1 the Company will spin off its Infection Prevention division into an independent company, NGD Infection Prevention, focused on the implementation of real-time genomic transmission detection across U.S. hospitals. The move is in response to the broadening recognition that sequencing of infection has become a practical means to detect and prevent transmission in hospitals and control the asso

There are currently no approved therapies to treat uncontrolled movements in cerebral palsy. Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure.The company’s Ingrezza (valbenazine), approved to treat certain uncontrolled movement conditions, failed to make a significant difference in a phase 3 trial for patients with dyskinesia due to cerebral palsy (CP), Neurocrine announced Monday.Ingrezza didn’t outperform placebo on imp

NUFYMCO® BLA has been approved by the USFDA AHMEDABAD, India and ZUG, Switzerland, Dec. 23, 2025 /PRNewswire/ -- Bioeq AG (" Bioeq"), a Swiss biopharmaceutical company, and Zydus Lifesciences Limited (" Zydus"), an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Va

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS23 December 2025 at 16.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds, and the total number of Orion shares owned directly, indirectly and thr